GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Distribution » Sichuan Goldstone Asia Pharmaceutical Inc (SZSE:300434) » Definitions » Total Assets

Sichuan Goldstone Asia Pharmaceutical (SZSE:300434) Total Assets : ¥2,835 Mil (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Sichuan Goldstone Asia Pharmaceutical Total Assets?

Sichuan Goldstone Asia Pharmaceutical's Total Assets for the quarter that ended in Sep. 2024 was ¥2,835 Mil.

During the past 12 months, Sichuan Goldstone Asia Pharmaceutical's average Total Assets Growth Rate was -2.00% per year. During the past 3 years, the average Total Assets Growth Rate was 7.70% per year. During the past 5 years, the average Total Assets Growth Rate was -2.00% per year. During the past 10 years, the average Total Assets Growth Rate was 37.40% per year.

During the past 13 years, Sichuan Goldstone Asia Pharmaceutical's highest 3-Year average Total Assets Growth Rate was 158.30%. The lowest was -11.90%. And the median was 7.05%.

Total Assets is connected with ROA %. Sichuan Goldstone Asia Pharmaceutical's annualized ROA % for the quarter that ended in Sep. 2024 was 2.68%. Total Assets is also linked to Revenue through Asset Turnover. Sichuan Goldstone Asia Pharmaceutical's Asset Turnover for the quarter that ended in Sep. 2024 was 0.08.


Sichuan Goldstone Asia Pharmaceutical Total Assets Historical Data

The historical data trend for Sichuan Goldstone Asia Pharmaceutical's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Goldstone Asia Pharmaceutical Total Assets Chart

Sichuan Goldstone Asia Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,230.26 2,494.20 2,768.13 3,059.91 3,101.44

Sichuan Goldstone Asia Pharmaceutical Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,050.72 3,101.44 3,105.40 2,809.38 2,834.72

Sichuan Goldstone Asia Pharmaceutical Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Sichuan Goldstone Asia Pharmaceutical's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=2424.066+677.373
=3,101

Sichuan Goldstone Asia Pharmaceutical's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets=Total Equity (Q: Sep. 2024 )+Total Liabilities (Q: Sep. 2024 )
=2436.855+397.868
=2,835

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sichuan Goldstone Asia Pharmaceutical  (SZSE:300434) Total Assets Explanation

Total Assets is connected with ROA %.

Sichuan Goldstone Asia Pharmaceutical's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %=Net Income (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=75.708/( (2809.376+2834.722)/ 2 )
=75.708/2822.049
=2.68 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Sichuan Goldstone Asia Pharmaceutical's Asset Turnover for the quarter that ended in Sep. 2024 is

Asset Turnover
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=234.716/( (2809.376+2834.722)/ 2 )
=234.716/2822.049
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Sichuan Goldstone Asia Pharmaceutical Total Assets Related Terms

Thank you for viewing the detailed overview of Sichuan Goldstone Asia Pharmaceutical's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Sichuan Goldstone Asia Pharmaceutical Business Description

Traded in Other Exchanges
N/A
Address
8 Jiayuan Road, 8th Floor, District A1, Dadi Xinguanghua Plaza, Chengdu, CHN, 610072
Sichuan Goldstone Asia Pharmaceutical Inc is engaged in development and application of steel-reinforced plastic composite pipe technology, providing customers with steel-reinforced plastic composite pipes from pipe structure, production process to construction technology. The company is also engaged in research and development, production and sales of medicines and health products.
Executives
Zheng Zhi Yong Director
Wei Bao Kang Directors, executives
Kuai Yi Xi Director
Chen Shao Jiang Executives
Lai Xing Feng Supervisors
Lin Qiang Directors, Directors, and Executives
Fu Hai Ying Directors, executives
Wang Shou Lun Supervisors
Li Run Xiu Supervisors

Sichuan Goldstone Asia Pharmaceutical Headlines

No Headlines